










































Reconstruction of the complete human cytomegalovirus genome
in a BAC reveals RL13 to be a potent inhibitor of replication
Citation for published version:
Stanton, RJ, Baluchova, K, Dargan, DJ, Cunningham, C, Sheehy, O, Seirafian, S, McSharry, BP, Neale,
ML, Davies, JA, Tomasec, P, Davison, AJ & Wilkinson, GWG 2010, 'Reconstruction of the complete human
cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication' Journal of Clinical
Investigation, vol 120, no. 9, pp. 3191-208. DOI: 10.1172/JCI42955
Digital Object Identifier (DOI):
10.1172/JCI42955
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Clinical Investigation
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Technical advance
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 9      September 2010  3191
Reconstruction of the complete human 
cytomegalovirus genome in a BAC reveals 
RL13 to be a potent inhibitor of replication
Richard J. Stanton,1 Katarina Baluchova,2 Derrick J. Dargan,2 Charles Cunningham,2 Orla Sheehy,2 
Sepehr Seirafian,1 Brian P. McSharry,1 M. Lynne Neale,1 James A. Davies,1 Peter Tomasec,1  
Andrew J. Davison,2 and Gavin W.G. Wilkinson1
1Section of Medical Microbiology, Tenovus Building, School of Medicine, Cardiff University, Cardiff, United Kingdom. 2MRC Virology Unit,  









































































3192	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 9      September 2010
Figure 1
Steps in the construction of pAL1111. The approximate location of the insertion site of the BAC vector between US28 and US29 in the 
US region of the HCMV genome is shown at the top. The designations of BACs (pAL series) and viruses (RCMV series) are shown on the 
right. Boxes indicate protein-coding regions (labeled), and circles denote loxP sites (L). The BAC box represents pBeloBAC11, the eGFP/
Puro box represents a cassette expressing eGFP and a puromycin resistance protein, and the Cre box represents a Cre recombinase gene 
containing a synthetic intron.
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Sequence differences between Merlin (NC_006273) and the HCMV genome in pAL1053
Position	 Change	(NC_006273	→	pAL1053)	 Coding	region	affected	 Coding	effect
11363 CAAAAAAAC → CAAAAAAAAC RL13 ƒ
40231 TTGGAGG → TTGCAGG UL32 None
48828 GGCGAAC → GGCAAAC UL36 R → C
49054 CATGATC → CATCATC UL36 I → M
49203 GACGGTA → GACAGTA UL36 R → C
49791 AGGGGTG → AGGAGTG UL36 P → S
49792 GGGGTGC → GGGCTGC UL36 H → Q
194592–194643 (1025–1076) ACACCCCCCGTCCCCGCACACCCCCCGTCCCCGCACACCCCCCGTCCCCG → G None (b/b′) None
195063 (605) GGACCGC → GGAGCGC None (b/b′) None
194781 CCGTAGA → CCGCAGA None (b′ only) None
Nt positions are given with respect to NC_006273. ƒ, frameshift. Altered bases underlined.
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Alignment of amino acid sequences potentially encoded by mutated versions of RL13 in pAL1031 and 10 other BACs from this stage, and PCR 
clones from Merlin (p5). Shading indicates identity to the WT Merlin sequence (NC_006273). Numbers in parentheses indicate the number of 
clones containing the relevant mutation. Nt mutations were as follows (numbering relative to strain Merlin sequence, NC_006273): mutant 1, 
C → T (nt 11573; premature stop codon); mutant 2, G → T (nt 11534; premature stop codon); mutant 3, C → T (nt 11531; premature stop codon); 
mutant 4 (which includes pAL1031), extra A (nt 11363; frameshift); mutant 5, G → C (nt 11563, W → C); mutant 6, deletion of nt 11276–11860; 
mutant 7, G → A (nt 11191, M → I, altered start codon; the protein is depicted as starting from next in-frame M).
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through  the monolayer  (Figure 5B) were  consistent with  the 
Table 2
Sequence differences between RL13 in WT Merlin (NC_006273) and subpopulations of Merlin (p3) represented in bacteriophage M13  
or PCR clones
Position	 Mutation	(NC_006273	→	clone)	 Residue	 Coding	effect	 No.	of	M13	clones	 No.	of	PCR	clones
11191 CATGCAC → CATACAC 1 M → I 1/6 0/22
11537 GAAGTGA → GAAATGA 117 V → M 4/8 11/22
11563 ATGGAAT → ATGCAAT 125 W → C 2/8 1/22
11563 ATGGAAT → ATGCAAT 125 W → C 2/8 4/22
11900 ATTGAAA → ATTCAAA 238 E → Q 2/8 4/22
11884 AATCGGG → AATTGGG 232 None 1/8 2/22
11964 TATCGGT → TATAGGT 259 S → X 1/8 2/22
Nt positions are given with respect to NC_006273. X, termination codon. Altered bases underlined.
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Properties of Merlin BAC–derived virus RCMV1111. (A) Restriction endonuclease profiles of DNA extracted from Merlin (p5), RCMV1111 (the 
virus derived from pAL1111), and pAL1111. Markers (kb) are shown. (B) Virus titers released into the medium following infection of HFFFs at 
an MOI of 0.01 PFU/cell. Error bars show mean ± SD; results are representative of 2 experiments. (C) Intracellular FACS staining for the US28 
protein in cells at various times PI with either Merlin (p5) or RCMV1111. Controls in the form of samples stained with IgG are shown. (D) Copy 
numbers of US29 transcripts relative to UL123 (IE1) transcripts at various times PI with Merlin (p5) or RCMV1111. Figures were averaged from 
3 experiments; error bars show mean ± SD. (E) Virus titers released into the medium following infection of HFFFs at an MOI of 0.01 PFU/ml with 
RCMV1158 or RCMV1111. Error bars show mean ± SD; results are representative of 2 experiments.
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WT (+), mutated (–) status of RL13 and UL128 in Merlin BACs
BAC	 Derived	virus	 RL13	 UL128
BACs	containing	no	tags
pAL1111 RCMV1111 – –
pAL1119 RCMV1119 + –
pAL1120 RCMV1120 – +
pAL1128 RCMV1128 + +
BACs	tagged	with	eGFP
pAL1158 RCMV1158 – –
pAL1159 RCMV1159 + –
pAL1160 RCMV1160 – +
pAL1161 RCMV1161 + +
BACs	containing	RL13	tagged	with	a	V5	epitope
pAL1279 RCMV1279 + –
pAL1280 RCMV1280 + +
BACs	tagged	with	eGFP,	tet	Operators	before	RL13/UL128L
pAL1393 RCMV1393 – + (tetO)
pAL1448 RCMV1448 + (tetO) –
pAL1498 RCMV1498 + (tetO) + (tetO)
Figure 4
Growth of BAC-derived viruses in HFFFs. Images show eGFP 
expressed by plaques formed in HFFFs 3 weeks PT with BAC DNA as 
indicated. Scale bars: 100 μm.
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Growth of BAC-derived viruses in HFFFs. (A) Areas of individual plaques at 3 weeks PT, with cells overlaid to prevent cell-free spread of virus. 
(B) Kinetics of infection measured by FACS analysis. (C) Kinetics of infectious virus release into the medium of the cultures in B, with error bars 
showing mean ± SD. (D) Area of plaques generated by virus harvested from the media in C, with each sample derived from the earliest time 
point at which more than 10 plaques were visible.
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Growth of BAC-derived viruses in ARPE-19s. (A) Size of plaques at 2, 
3, or 4 weeks PT, with cells overlaid to prevent cell-free spread of virus. 
(B) Kinetics of infection following transfection of BACs into ARPE-19s 
without overlay, measured by FACS analysis of eGFP. (C) Kinetics of 
infectious virus release into the medium of the cultures in B, with error 
bars showing mean ± SD.
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RL13 and UL128L mutations detected by PCR in BAC-derived viruses at p3
Stock	 RL13	mutations	 UL128L	mutations
	 Mutation	 Position	 Affected	clones	(%)	 Effect	 Mutation	 Position	 Affected	clones	(%)	 Effect
RL13+UL128–	BAC	transfected	into	HFFFs
1 ^A 11363 33 ƒ    
1 G → T 11901 40 E → X    
2 ΔA 11363 30 ƒ    
3 ^A 11363 50 ƒ    
4 A → G 11297 20 S → G    
4 C → T 11427 20 A → V    
4 A → G 11956 20 I → M    
RL13–UL128+	BAC	transfected	into	HFFFs
5     C → T 176229 14 R → Q
5     T → C 176845 14 I → V
5     CAAGA → TCTTG 176915-9 21 FL → SA
6     ΔT 176456 30 None (intron)
7     None  100 None
RL13–UL128+	BAC	transfected	into	ARPE-19s
8     None  100 None
9     A → G 176917 20 None
RL13+UL128+	transfected	into	HFFFs
10 None  100  ΔT 176456 50 None (intron)
11 ^A 11363 20 ƒ None  100 None
12 None  100  ΔT 176456 30 None (intron)
13 None  100  ΔT 176456 30 None (intron)
Each row represents an individual virus stock. Nt positions are given with respect to NC_006273. +, WT gene; –, mutated gene; ^, inserted nt; Δ, deleted nt.
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Characterization of gpRL13. (A 
and B) Western blot performed on 
RL13V5, showing the sizes of the 
proteins in native form or following 
digestion with EndoH or PNGaseF. 
RL13V5 was either expressed in 
isolation from a RAd (A) or from its 
native position in RCMV1279 (B). 
(C) Immunofluorescence performed 
for the indicated antigens on HFFFs 
infected with the RAd express-
ing RL13V5 (×640 magnification). 
(D and E) Immunofluorescence 
performed for the indicated anti-
gens either on HFFFs infected with 
RCMV1279 or on ARPE-19s infect-
ed with RCMV1280. Original magni-
fication, ×640.
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Localization of RL13 in the virion. (A) Western blot per-
formed on purified virions from virus expressing a trun-
cated gpRL13 (RCMV1111, RL13–) or full-length RL13 
with a C-terminal epitope tag, gpRL13V5 (RCMV1279, 
RL13+). Complete virions (V), envelope fraction (E), 
and tegument/capsid fraction (T) were probed for 
the antigens indicated. (B) Immunogold EM staining 
for RL13V5 in purified RCMV1279 virions. Original 
magnification, ×40,000.
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Figure 9
Repression of UL128L and RL13 by 
BAC-derived viruses in HFFF-tet cells. 
(A) FACS analysis of parental HFFFs 
or HFFF-tet cells, infected with empty 
control adenovirus (RAd-Ctrl) or RAd-
expressing eGFP (RAd-GFP). RAd-
GFP expresses GFP from the HCMV 
MIE promoter, containing 2 tet opera-
tors 10 bp downstream of the TATA 
box. (B–E) Plaque sizes of viruses 
generated at 2 weeks PT in HFFFs (B 
and D) or HFFF-tet cells (C and E), with 
cells overlaid to prevent cell-free spread 
of virus, showing (B and C) repression 
of UL128L in RCMV1393 and (D and 
E) repression of RL13 in RCMV1448. 
(F) Titers of virus stocks obtained from 
HFFF-tet cells infected with viruses in 
which RL13 and UL131A were tet con-
trolled (RCMV1448 and RCMV1393, 
respectively) or the parental viruses 
in which RL13 and UL131A were 
not tet controlled (RCMV1159 and 
RCMV1160, respectively). (G) Plaque 
size of parental virus (RCMV1160) or 
virus in which UL131A was tet con-
trolled (RCMV1393) in ARPE19 cells, 
3 weeks PT.
technical advance





























































































Simultaneous repression of UL128L and UL13 by BAC-
derived viruses in HFFF-tet cells. Plaque sizes of virus-
es generated at 3 weeks PT in HFFFs (A) or HFFF-tet 
(B) cells, with cells overlaid to prevent cell-free spread 
of virus. Data points represent individual plaque sizes 
recorded for each mutant.
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underlined). The amplified fragment was digested with PacI and inserted 
into PacI-digested pAL815, thus generating pAL1026.









Repairing of Merlin BACs. Recombineering was performed in E. coli SW102 
using lacZ/ampr/sacB (62) and galK selection cassettes (82) as previously 
described. The sequences of the primers used are listed in Supplemen-
tal Table 1  (supplemental material  available online with  this article; 
doi:10.1172/JCI42955DS1). All constructs were verified by sequencing 
modified regions and by restriction digest at each step. To enable the 
Merlin UL29–UL34  sequence  to  be  reintroduced  into  pAL1031,  the 
lacZ/ampr/sacB cassette was amplified and inserted between the loxP site 
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